DEF: Waters Corporation Aims for New Growth Era with Board Refreshment and Strategic Initiatives

Waters Corporation is entering a new era of growth, focusing on operational excellence, new product launches, and expanding into adjacent markets, while maintaining strong corporate governance and shareholder returns.

Summary

• Waters Corporation is embarking on a new phase of growth, building on a transformation journey that began in 2020.
• The company has regained commercial momentum, revitalized its portfolio, and expanded into rapidly growing adjacent markets.
• In 2024, Waters navigated market headwinds to achieve flat revenues but expanded GAAP and adjusted operating income margins to 27.9% and 31.0%, respectively.
• The company has delivered top-tier total shareholder returns for the fourth consecutive year, leading its Life Science tools peer group.
• Waters is focused on operational excellence, capitalizing on new product launches, and deepening customer relationships globally.
• Strategic initiatives have enabled Waters to establish a strong instrument replacement cadence, increase service attachment rates to over 50%, drive eCommerce adoption with over 40% of chemistry revenue generated online, and increase contract organizations representing 25% of pharmaceutical revenue.
• The company has revitalized its portfolio with innovative product launches and continued to allocate resources to enter faster-growing adjacencies such as bioseparations, bioanalytical characterization, specialty diagnostics, and battery testing.
• The Board of Directors is composed of 10 directors with expertise in global markets, science and technology, manufacturing, strategic planning, and mergers and acquisitions.
• Heather Knight was welcomed as a new independent director in August 2024, bringing expertise in the pharmaceutical and medical device industries.
• The company's 7,600 global employees collaborate with customers to solve their greatest scientific challenges.
• The Annual Meeting of Shareholders will be held virtually on May 22, 2025, with several proposals to be voted on, including the election of directors, ratification of the independent accounting firm, and approval of executive compensation and the Amended and Restated 2009 Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting growth initiatives and strong shareholder returns, but acknowledges challenges such as flat revenue and market headwinds. The sentiment is moderately positive.

Positives

• Waters Corporation is entering a new era of growth.
• The company has regained commercial momentum, revitalized its portfolio, and expanded into rapidly growing adjacent markets.
• Waters achieved flat revenues but expanded GAAP and adjusted operating income margins in 2024.
• The company has delivered top-tier total shareholder returns for the fourth consecutive year.
• Strategic initiatives have increased service attachment rates and driven eCommerce adoption.
• The Board of Directors is composed of highly qualified individuals with diverse expertise.
• The Board was named the 2024 Public Company Board of the Year by the National Association of Corporate Directors (NACD) New England Chapter.

Negatives

• Revenues were flat for 2024.
• China's revenue declined by 10% due to lower customer demand for instrument systems and chemistry products as a result of increased government regulations and macroeconomic conditions.

Risks

• The company faces market headwinds, including significant foreign exchange impacts.
• The company's future results may differ significantly from forward-looking statements due to various factors, including those discussed in the company's Annual Report on Form 10-K.
• Cybersecurity risks are a concern, and the company is actively working to manage and mitigate these risks.

Future Outlook

Waters is entering a new phase of growth in 2025, building on its transformation by embedding excellence in execution, continuing to deliver pioneering innovation, and scaling up in high-growth areas.

Management Comments

• Dr. Flemming Ornskov, M.D., M.P.H., Chair of the Board: 'Waters is entering a new era of growth.'
• Udit Batra, Ph.D., President and Chief Executive Officer: 'Throughout 2024, Waters has remained focused on operational excellence, capitalizing on the success of our new product launches and deepening our relationships with customers globally.'

Industry Context

Waters operates in the life science tools industry and competes with companies like Agilent, Avantor, Bio-Rad, Bio-Techne, Bruker, Danaher, Mettler Toledo, Revvity, and Thermo Fisher Scientific. The company's performance is evaluated against these peers.

Comparison to Industry Standards

• Waters' total shareholder return (TSR) has been ahead of all major Life Science Tools peers since the beginning of its transformation in July 2020.
• In 2024, the company delivered 13% TSR, which was the highest amongst Life Science Tools peers.
• The company uses a core industry peer group of 17 publicly traded companies in the life sciences and analytical instrument industry with generally similar revenues and market capitalization as Waters for executive compensation decisions.
• The peer group includes Agilent, Avantor, Bio-Rad Laboratories, Bio-Techne, Catalent, Charles River Laboratories, Cooper Companies, Edwards Lifesciences, Hologic, IDEXX Laboratories, Illumina, Mettler-Toledo, ResMed, Revvity, STERIS, Teleflex, and West Pharmaceutical.

Stakeholder Impact

• Shareholders are expected to benefit from the company's focus on growth and shareholder returns.
• Employees are expected to benefit from the company's focus on human capital management and talent development.
• Customers are expected to benefit from the company's focus on operational excellence and new product launches.

Next Steps

• Shareholders are asked to vote on several proposals at the Annual Meeting on May 22, 2025.
• The Board and management team will continue to prioritize effective oversight of the company's people.
• The company will continue to evaluate M&A opportunities that will enhance value creation for shareholders.

Key Dates

Keywords

Waters Corporation, shareholder returns, corporate governance, financial performance, executive compensation, board of directors, life sciences, analytical instruments, proxy statement, stock purchase plan